ClinicalTrials.gg
RecruitingNCT07628946Updated Jun 5, 2026

Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy

An observational study in Ocular Surface Disease, Inflammatory Disease and Retinal Disease, sponsored by Dan Chen. Recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Dan Chen · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Retinal Diseases with a site in China — 12 open to participants now, 14 under way, 1 of them phase 3. Retinal Diseases · China.

Planned enrollment
7th of 17
3,000 · median 2,000
Started
2025
with 3 others
Observational
17 of 29
7 open now
Primary completion
2030-02
later than 12 of 13 live
Registered
27th of 29
by date
Lead sponsor
1 of 29
Dan Chen

Among the 29 studies in Retinal Diseases with a site in China, this one is the 7th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2025, is one of 17 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 27th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

12 of the 29 studies in Retinal Diseases with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Retinal Diseases with a site in China, or all of them as a file.
02

Study summary

Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related macular degeneration and the changes in fine parameters of the anterior structure of the eye are deeply explored. To achieve this goal, investigators will adopt cutting-edge multimodal imaging technology to simultaneously collect precise data from ocular surface and fundus of participants. By integrating and analyzing these multi-dimensional information from different parts of the same eye, investigators will build a high-quality and standardized ocular surface-fundus associated image database. This database not only aims to reveal potential ocular surface biomarkers that can be used for early warning or auxiliary diagnosis, but also lays a solid data foundation for the future development of artificial intelligence-assisted diagnostic tools and the establishment of a brand-new ocular surface-fundus integrated diagnosis and treatment assessment model.

03

Conditions studied

  • Ocular Surface Disease
  • Inflammatory Disease
  • Retinal Disease
  • Choroid Diseases
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients with both inflammatory and non-inflammatory ocular diseases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Retinal vascular and metabolic-related diseases: Diabetic Retinopathy (DR, including NPDR and PDR), Retinal Vein Occlusion (RVO), Hypertensive Retinopathy.
  2. Degenerative diseases: Age-related Macular Degeneration (including dry and wet forms), Pathologic Myopia (PM), Polypoidal Choroidal Vasculopathy (PCV).
  3. Immune-mediated and inflammatory eye diseases: Uveitis (including primary and secondary), Optic Neuritis, Mooren's Ulcer, and corneal melting associated with systemic immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  4. Anterior segment and ocular surface syndromes: Various types of Dry Eye Disease (DED), Keratoconus, Glaucoma (especially cases with chronic inflammation or long-term medication use).
  5. Developmental fundus diseases in children and adolescents: Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP).
  6. Patients with a confirmed diagnosis of fundus diseases, including Diabetic Retinopathy, Pathologic Myopia, Age-related Macular Degeneration, Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP), and other adult or pediatric fundus diseases.
  7. Ability to cooperate with study examinations, including acceptance of Ultra-Widefield (UWF) fundus photography, OCT/OCTA, AOSLO, corneal confocal microscopy, meibomian gland function assessment, corneal esthesiometry, and tear film function tests. Image quality must meet analytical standards.
  8. Availability of complete or follow-up accessible ophthalmic medical records.
  9. Blood pressure ≤ 160/100 mmHg (to avoid exacerbating ischemia due to uncontrolled hypertension).

Exclusion criteria

Exclusion Criteria:

  1. Recent (within the past 3 months) corneal/conjunctival acute inflammation, ocular surgery, or ocular trauma; or presence of corneal alterations (e.g., contact lens wear).
  2. Fundus images that are uninterpretable or severely obscured (e.g., vitreous hemorrhage).
  3. Use of medications affecting tear secretion (e.g., antihistamines, antidepressants) within the past 30 days.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Inflammatory-Related Ocular Disease Group
  • Non-Inflammatory-Related Ocular Disease Group
06

What researchers measure

Primary outcomes

  1. Tear Break-Up Time

    The time from the last complete blink to the appearance of the first dry spot on the cornea.

    Time frame: Baseline and within 30 days post-procedure

  2. Dry Eye Questionnaire-5

    The DEQ-5 comprises five items assessing the frequency of dryness, discomfort, and watery eyes, as well as the late-day intensity of dryness and discomfort. Patients rate each item on a 0-4 or 0-5 scale, and the total score is summed. Higher scores indicate greater dry eye symptom severity.

    Time frame: Baseline and within 30 days post-procedure

  3. Meibomian Gland Dropout

    Meibomian gland dropout will be measured using infrared meibography.

    Time frame: Baseline and within 30 days post-procedure

  4. Blink Rate

    Blink rate will be measured using a video recording system under natural blinking conditions. The number of complete blinks and incomplete blinks per minute will be counted separately.

    Time frame: Baseline and within 30 days post-procedure

  5. Lipid Layer Thickness

    Lipid layer thickness refers to the thickness of the lipid layer of the tear film, which is the outermost layer of the precorneal tear film.

    Time frame: Baseline and within 30 days post-procedure

  6. Tear Meniscus Height

    Tear meniscus height refers to the vertical height of the tear volume accumulated along the lower eyelid margin.

    Time frame: Baseline and within 30 days post-procedure

Secondary outcomes

  1. Central Subfield Thickness

    Central subfield thickness refers to the thickness of the retina at the fovea.

    Time frame: Baseline and within 30 days post-procedure

  2. Subfoveal Choroidal Thickness

    Subfoveal choroidal thickness refers to the thickness of the choroid directly beneath the fovea.

    Time frame: Baseline and within 30 days post-procedure

  3. Subretinal Fluid

    Subretinal fluid refers to fluid accumulation in the potential space between the neurosensory retina and the retinal pigment epithelium.

    Time frame: Baseline and within 30 days post-procedure

  4. Intraretinal Fluid

    Intraretinal fluid refers to fluid accumulation within the retinal layers, typically appearing as cystoid spaces.

    Time frame: Baseline and within 30 days post-procedure

  5. Pigment Epithelial Detachment Height

    Pigment epithelial detachment height refers to the maximal vertical height of separation of the retinal pigment epithelium from the underlying Bruch's membrane.

    Time frame: Baseline and within 30 days post-procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Feb 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 5, 2026
StartActual
Nov 26, 2025
Primary completionEst.
Feb 2030
CompletionEst.
Feb 2030
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07628946
Lead sponsor
Dan Chen
Responsible party
Dan Chen (Investigator, Capital Medical University) — Sponsor-investigator
First posted
Jun 5, 2026
Start date
Nov 26, 2025
Primary completion
Feb 2030 (estimated)
Completion
Feb 2030 (estimated)
Last update
Jun 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion